- Details
- Ali Sabbagh presents a novel study on using machine learning to predict overall survival in clinical trials for metastatic prostate cancer. Dr. Sabbagh explains that traditional endpoints like overall survival often require long follow-ups, delaying access to potentially life-saving treatments. His research leverages baseline clinical characteristics and PSA changes over four months to accelerate...
|
- Details
- Rahul Aggarwal presents findings on targeting DLL3 in neuroendocrine prostate cancer. He explains that DLL3 is highly expressed in high-risk neuroendocrine prostate cancer, particularly in the treatment-emergent form seen after androgen deprivation therapy. This Phase 1b study expanded on prior research in small cell lung cancer and included 40 patients with broad inclusion criteria for DLL3 posit...
|
- Details
- Edmond Kwan discusses his latest research on circulating tumor DNA (ctDNA) as a predictive marker for response to Lutetium PSMA-617 versus cabazitaxel. The Phase II TheraP trial compared these treatments in patients with advanced metastatic castration-resistant prostate cancer, utilizing dual imaging selection. Dr. Kwan highlights that ctDNA fraction, the proportion of tumor-derived DNA in circula...
|
- Details
- Zach Klaassen and Alicia Morgans discuss the findings from an exploratory analysis of the ARAMIS trial, focusing on the efficacy of darolutamide for non-metastatic castration-resistant prostate cancer (nmCRPC). Dr. Morgans explains that darolutamide, approved after the ARAMIS phase 3 trial, significantly improves metastasis-free survival by 22 months and reduces mortality by 31% compared to placeb...
|
- Details
- Zach Klaassen and Khalid Alkhatib discuss the significant cardiovascular risks faced by testicular cancer survivors. Dr. Alkhatib explains that the exact mechanisms behind this increased risk are not fully understood but are thought to be related to chemotherapy, particularly with Cisplatin, and associated conditions like metabolic syndrome and hypogonadism. Their study, utilizing a 15-year nation...
|
- Details
- Deepak Kilari discusses a Phase II trial exploring the combination of enzalutamide with five alpha-reductase inhibitors (ARIs) for castrate-sensitive prostate cancer. Driven by observations from geriatric oncology, the study seeks alternatives to androgen deprivation therapy (ADT) for older, frail men who struggle with its side effects. The trial examines whether enzalutamide combined with dutaste...
|
- Details
- Scott Tagawa discusses the final results of a phase I/II trial exploring dose-escalation of lutetium PSMA for advanced prostate cancer. Launched in 2017, this trial aimed to determine the safety and efficacy of increasing radioactive doses in a fractionated, dose-dense regimen to maintain constant tumor exposure. The study escalated doses from 7.4 to 22.2 gigabecquerels without reaching a dose-lim...
|
- Details
- Anthony Joshua presents the findings of the MAST trial, a decade-long investigation into the use of metformin for men with low-risk prostate cancer under active surveillance. Conducted across 12 Canadian centers, this randomized Phase III study involved 408 men and aimed to determine if metformin could delay cancer progression. Despite earlier promising studies suggesting potential benefits, the t...
|
- Details
- Daniel Kwon presents a study on genetic counseling for Veterans with advanced prostate cancer. This mixed-methods research combines in-depth qualitative interviews and quantitative surveys to evaluate how well Veterans understand and make decisions about genetic testing. Initial interviews with 31 patients reveal that most found the decision straightforward, but some had uncertainties about the im...
|
- Details
- Zach Klaassen discusses the ARASTEP trial with Alex Chehrazi-Raffle. The trial focuses on patients with high-risk biochemical recurrence of prostate cancer, specifically those who show positive results on PSMA PET scans but are negative on conventional imaging. Dr. Chehrazi-Raffle explains that ARASTEP, a randomized phase 3 study, aims to evaluate the efficacy of combining androgen deprivation the...
|
